Abstract
Prostate cancer represents the leading cause of cancer in men, with an estimated incidence of 180,890 cases in 2016. Long-term outcomes reveal equivalent biochemical outcomes with brachytherapy (BT) compared to radical prostatectomy and external beam radiotherapy (EBRT). Iodine-125 (125I) and Palliadium-103 (103Pd) represent the most commonly used isotopes for prostate BT, however, a significant proportion of men receiving 125I prostate-BT incur long term urinary consequences lasting beyond 1 year. Cesium-131 (131Cs) was introduced as an alternative isotope in 2004. Given the higher dose rate and shorter dose delivery time with 131Cs BT, the duration of urinary morbidity is predicted to be shorter. Unfortunately, to date only a few centers have reported their oncologic outcomes with use of 131Cs radionuclide, though long-term data remains lacking. Therefore, we report here our institution’s high-volume experience and [[Unsupported Character - Codename ]] [[Unsupported Character - Codename ]] the most mature data to date on outcomes with 131Cs prostate BT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
